用钇-90和铟-111标记的1,4,7,10-四氮杂环十二烷-N,N',N",N"'-四乙酸（DOTA）螯合物对嵌合单克隆抗体L6进行预标记，用于放射免疫诊断和治疗。
Prelabeling of chimeric monoclonal antibody L6 with 90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy.
作者信息
Li M, Meares C F, Salako Q, Kukis D L, Zhong G R, Miers L, DeNardo S J
机构信息
Department of Chemistry, University of California, Davis 95616, USA.
出版信息
Cancer Res. 1995 Dec 1;55(23 Suppl):5726s-5728s.
PMID:7493335
Abstract
90Y and 111In have been attached to chimeric monoclonal antibody L6 with a bifunctional chelating agent (DOTA-peptide isothiocyanate). The bifunctional chelating agent was prelabeled with either radiometal and then conjugated to the antibody. Studies in human patients showed excellent 111In single-photon emission computed tomography images of breast cancer lesions 24 h after injection.
摘要
已使用双功能螯合剂（DOTA-肽异硫氰酸酯）将90Y和111In附着于嵌合单克隆抗体L6。双功能螯合剂先用两种放射性金属之一进行预标记，然后与抗体偶联。在人类患者中进行的研究显示，注射后24小时乳腺癌病灶的111In单光子发射计算机断层扫描图像效果极佳。
Zotero 插件